Recombinant human parathyroid hormone (1–34)
Intermittent administration of recombinant human parathyroid hormone (1–34) (20 μg/day) increases osteoblast formation and inhibit osteoblast apoptosis, which results in an increase in bone turnover and formation. It is the first osteoporosis treatment that leads to the formation of new bone with architecture similar to normal bone. Overall there is a net increase in bone with each PTH cycle, thus reducing the risk of fragility fractures.
Treatment of post-menopausal osteoporosis and male/female osteoporosis secondary to hypogonadism, sex steroid deficiency, rheumatoid arthritis, and certain malignancies in which bone resorption occurs in excess of bone formation and the patient is at very high risk for having bone fractures.